



Prior Authorization Approval Criteria

Amrix (cyclobenzaprine, extended release)

Generic name:	Cyclobenzaprine, extended release
Brand name:	Amrix
Medication class:	Muscle relaxant
FDA-approved uses:	Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions
Available dosage forms:	15 mg and 30 mg capsules
Usual dose range:	15 mg to 30 mg once daily
Duration of therapy:	Periods longer than 2 or 3 weeks are not recommended.
Approximate monthly cost: (based on AWP 2007)	15 mg capsule ER \$236.25 30 mg capsule ER \$226.80

Criteria for use (bullet points below are all inclusive unless otherwise noted):

- Clinically diagnosed muscle spasms.
- Tried and failed immediate-release cyclobenzaprine (Flexeril).
- Failed/intolerant to at least 2 FCHP preferred alternative muscle relaxants, such as dantrolene, baclofen, orphenadrine, methocarbamol, diazepam, and chlorzoxazone.

Contraindications:

- Hypersensitivity to any product component.
- Concomitant use of MAO inhibitors or within 14 days after their discontinuation.
- During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block conduction disturbances or congestive heart failure.
- Hyperthyroidism.

Not approved if:

- Patient has any contraindications to the use of cyclobenzaprine.
- Patient does not meet the above stated criteria.

Comparative cost information:

Amrix (cyclobenzaprine, extended-release):	15 mg capsules	1 capsule QD	\$249.00
	30 mg capsules	1 capsule QD	\$249.00
Flexeril (cyclobenzaprine immediate release):	5 mg tablets	1 tablet TID	\$149.00
	10 mg tablets	1 tablet TID	\$135.00
Cyclobenzaprine immediate release (generic):	5 mg tablets	1 tablet TID	\$51.20
	10 mg tablets	1 tablet TID	\$13.50

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 12/12/07